



We want to save patients with severe cancer and autoimmune diseases
Entering clinical phase with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO, August 2017


Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

Why invest in Cantargia?

- Focus on immuno-oncology - the strongest growing pharmaceutical segment
 - Taking advantage of the well established antibody technology to design novel targeted pharmaceuticals
- Lead candidate antibody CAN04 with double mechanism of action entering clinical stage with multiple value inflection points 2017-2019
 - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
 - Important clinical safety and efficacy data expected in the next 12 months
- Second generation antibodies developed for auto immune disease
- Unique and strong IP
- Lead investors with high competence and strong track record
- Management and chairman with solid competence in clinical development

Lead project CAN04 in the highest growth segment— Oncology antibodies



World's most sold cancer drugs are antibodies (2016)

Rituxan/MabThera	\$8.58bn
Avastin	\$6.75bn
Herceptin	\$6.75bn

Immuno-oncology driving market growth (2016)

Opdivo	\$3.77bn	(\$0.94bn)
Keytruda	\$1.40bn	(\$0.57bn)

Source IMS Health

Cantargia at a glance

Specialized in antibody therapy/immunology, with initial focus on oncology
Granted IP on therapeutic target and drug candidates
Lead antibody CAN04 in clinical stage from Q3 2017
Strong management team with proven track record in clinical development and business development
IPO March 2015 (Nasdaq First North, Stockholm)
c. 3000 shareholders incl specialist and strong long term investors
Based in Lund, Sweden

Financial highlights

Share price: 6.20 SEK (0.77 USD), Aug 23, 2017


Market cap: 199 MSEK (24.6 MUSD), Aug 23, 2017

Cash: 66.5 MSEK (8.2 MUSD), June 30 2017

Current owners (June 30, 2017)

LU Bio	12.6%
Sunstone	7.2%
Avanza Pension	6.4%
David Olsson	2.5%
Brushamn Invest	2.5%
Kudu AB	2.4%
Thoas Fioretos	2.3%
Marcus Järås	2.3%
Mats Invest AB	2.2%
Akademihemman	2.2%
Others	57.4%

Cantargia pipeline




Recent News Flow


- CAN04 clinical trial application – regulatory approval (July 2017)
- Collaboration agreement with Panorama Research Inc (Sunnyvale, CA) (June 2017) on antibody development in auto immune disease
- CAN04 patent application - intention to grant by EPO, notice of allowance US (April/June 2017)
- CAN04 strong safety data in GLP studies (May 2017)

IL1RAP - a novel target on cancer cells

Normal cell






Cancer cell



- IL1RAP identified as a cancer target (several cancer forms)
- IL1RAP regulates inflammation (incl. IL-6 and IL-8)
- Cantargia's lead candidate CAN04 is an antibody against IL1RAP

CAN04 - immuno-oncology mechanism with antitumor effect



- Antitumor effects in NSCLC PDX models
- CAN04 stimulates immune cells to infiltrate tumor

CAN04 Clinical Development

Phase I/IIa trial - NSCLC and pancreatic cancer


Approval to start in Norway and Denmark

Review ongoing in Belgium and Netherlands

Adaptive design (phase IIa part final design based on phase I and preclinical data)

Phase IIa in leukemia


Planned to start after phase II dose defined 2018



CAN04 - Several shots on goal


Focus on three cancer forms with different biological properties, challenges, prognosis and strategic opportunities

Next step development can focus on cancer form(s) with strongest efficacy signal



IL1RAP - additional potential indications to leverage the value of our asset

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP




Strategic partnership with Panorama Research Inc

Panorama Research Inc

Privately-owned biomedical R&D company in Silicon Valley California

Leader in antibody technology, managed by Dr James W. Larrick

Deal structure: Panorama share risk in exchange for a fraction of future incomes



Panorama Research, Inc
A Biotechnology Research & Development Company

Development of new antibody binding IL1RAP with high affinity/potent inhibition of signaling

Focus on autoimmune/inflammatory disease

Selection of clinical candidate 2019

Cantargia IL1RAP antibody, affinity matured and humanized using Panorama's proprietary technology

Panorama also generates cell lines optimized for high level GMP production

Cantargia responsible for subsequent development

Management



Göran Forsberg

CEO since 2014, born 1963

Göran Forsberg has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. He has worked for pharmaceutical and biotechnology companies for more than 25 years in various positions, including at KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg's most recent position was Chief Business Officer at Active Biotech AB. He has a large amount of drug development experience, with a special focus on oncology. Since 2011, Forsberg is a board member of Isogenica Ltd. Shares in Cantargia: 48,350



Lars Thorsson

VP Clinical Development since 2015, born 1961

Lars Thorsson graduated with a Ph.D. in clinical pharmacology in 1998. Thorsson has more than 25 years experience in the pharmaceutical industry, including leading roles in clinical studies and project management in a large number of development phases at AstraZeneca. Thorsson's most recently worked at Novo Nordisk A/S, where he held the role of Senior Clinical Pharmacology Scientist, responsible for preparation and implementation of clinical pharmacological studies in development projects. Thorsson has been responsible for evaluation and documentation of new substances and has the experience of regulatory activities and interactions with health authorities. Shares in Cantargia: 24,998



Bengt Jöndell

CFO since May 2017, born 1960.

Bengt Jöndell has a BSc in Business Administration and a MSc in Chemical engineering. Jöndell has extensive experience in various executive financial functions such as CFO and Chief Executive Officer at BTJ Group AB, Senior Financial Advisor for BoneSupport, CFO/Administrative manager at Inpac, Business Controller at Pharmacia & Upjohn Consumer Healthcare, Pharmacia, Pharmacia Consumer Pharma and Pharmacia Nicorette. Jöndell's most recent position was CFO for Enzymatica AB. Shares in Cantargia 10,000



Liselotte Larsson

VP Operations since 2014, born 1963

Liselotte Larsson has a PhD in biotechnology, and has more than 20 years of experience in various management positions in pharmaceutical and biotechnology companies including BioGaia Fermentation, Novozymes Biopharma and Camurus. Larsson's main fields of expertise are business development, marketing & sales/out licensing, regulatory certification, good manufacturing practice (GMP) and overall project management. Shares in Cantargia: 15,000



David Liberg

VP Cancer Research since 2015, born 1969

David Liberg graduated with a Ph.D. in 2001 and has nearly twenty years of research experience within immunology and tumour biology. Liberg has worked within the pharmaceutical industry for the last ten years, with responsibility for early research projects and activities within tumour immunology. He has extensive experience of pre-clinical phases of cancer projects. His most recent position was at Active Biotech AB, where he worked as Project Manager Drug Development as well as Head of Cell Biology and Biochemistry. Liberg has also carried out research at Imperial College in the UK and at Lund University, Sweden. Shares in Cantargia: 2,000

Board of Directors



Magnus Persson

Chairman of the Board since 2016, born 1960

Magnus Persson is MD and associate professor in physiology at Karolinska Institutet in Stockholm. Persson has a large amount of experience in the fields of medicine, life sciences and biotech-financing. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as chairman or member of the board, in Europe and the USA. Persson has also been involved in multiple IPOs. Shares in Cantargia: 28,110 and 85,000 options



Lars H. Bruzelius

Board member since 2013, born 1943

Lars H. Bruzelius is an associate professor in Business Administration and management consultant with many years of experience working with banks and companies in the energy, medtech and telecommunication industries. Bruzelius is a senior partner in and joint owner of BSI & Partners, and has been a board member and chairman of LU Bioscience AB since 2012. For three years, Bruzelius was the Deputy Chief Executive and Administrative Director of Gambro AB. Bruzelius has been a board member of two listed companies as well as an investor and board member of a number of start-up companies. Shares in Cantargia 792,577



Niclas Lundqvist

Board member since 2016, born 1965

Niclas Lundqvist is a Master of Law at law firm Advokatbolaget Wiklund Gustavii. Since 1996, he has specialized in legal counselling with companies listed on the Swedish stock market or MTF. Lundqvist has operational experience from boards of companies listed on the Swedish stock market and companies under the supervision of Finansinspektionen. His previous experience includes other types of legal work, project management and business development in Corporate Finance at Sedermera Fondkommission from 2003 to 2013. Lundqvist is one of the founders of venture capital fund 'Swedish Growth Fund'. Shares in Cantargia: 0



Karin Leandersson

Board member since 2016, born 1972

Karin Leandersson is associate professor and lecturer in tumour immunology at the medical faculty of Lund University. She has gained a wide range of cancer research experience in the fields of tumour immunology and tumour inflammation in solid tumours, mainly in breast cancer. Leandersson has also authored around 30 scientific publications in international journals. Shares in Cantargia: 0



Claus Asbjørn Andersson

Board member since 2013, born 1968

Claus Asbjørn Andersson is a partner of Sunstone Life Science Ventures, a holding company managing billion-dollar venture funds. He has a Master's degree in Civil Chemical Engineering from Technical University of Denmark and a PhD in Mathematical Statistics from Copenhagen University and Humboldt University of Berlin. Andersson has himself founded four European start-up companies, including two in Denmark. He has been with Sunstone Life Sciences since its establishment in 2007, and is an active member of the International Venture Club and advisor to the European Commission. Shares in Cantargia: 0



Thoas Fioretos

Board member since 2010, born 1962

Thoas Fioretos is a professor and physician at the Department of Clinical Genetics at Lund University. The focus of his research is molecular and functional studies of genetic changes in leukaemia and how such changes can be used for diagnostic and therapeutic purposes. Fioretos has authored many scientific publications, and is one of the founders of Cantargia AB and bio-IT company Qlucore AB. Shares in Cantargia: 732,600

Significant value inflection points ahead

2017

- Initiation of phase I/IIa trial
- Preclinical data on combination therapy

H1 2018

- Presentation of Phase I clinical data
- Initiation of Phase IIa portion of the clinical trial
- Preparations for the clinical phase IIa of leukemia

Why invest in Cantargia?

- *Focus on immuno-oncology - the strongest growing pharmaceutical segment*
 - *Taking advantage of the well established antibody technology to design novel targeted pharmaceuticals*
- *Lead candidate antibody CAN04 with double mechanism of action entering clinical stage with multiple value inflection points 2017-2019*
 - *Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)*
 - *Important clinical safety and efficacy data expected in the next 12 months*
- *Second generation antibodies developed for auto immune disease*
- *Unique and strong IP*
- *Lead investors with high competence and strong track record*
- *Management and chairman with solid competence in clinical development*

Investerardagen

Stockholm 28 augusti, 2017



09.15-09.35 PAUS - kaffe, te och vatten